Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

and anti-CD38 monoclonal antibody, and Regeneron is planning to file linvoseltamab in the same setting. Dosing could be another point of difference for the new drug. Elrexfio has a slight edge ...

For mRNA vaccines, there are various ways that they can be used against cancer, including in adoptive T-cell therapies, therapeutic antibodies ... and Regeneron’s Libtayo (cemiplimab), a ...

“Immune checkpoint inhibitors … these are IV therapies — antibodies — that wake up the immune system ... pembrolizumab (Keytruda®), atezolizumab (Tecentriq®), and cemiplimab (Libtayo®). Of note, these ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial - - Data presented at AACR 2023 supports ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...